U.S. Markets open in 9 hrs 24 mins

ORIC Pharmaceuticals, Inc. (ORIC)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
19.48+0.45 (+2.36%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close19.03
Open18.84
Bid18.50 x 1200
Ask19.80 x 1200
Day's Range18.64 - 19.63
52 Week Range18.18 - 40.81
Volume136,146
Avg. Volume228,949
Market Cap714.834M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateMay 18, 2021 - May 24, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est43.14
  • Oric Pharma's ORIC-101 Shows Tumor Regression, Prolonged Stable Disease in Multiple Heavily Pretreated Tumors
    Benzinga

    Oric Pharma's ORIC-101 Shows Tumor Regression, Prolonged Stable Disease in Multiple Heavily Pretreated Tumors

    Oric Pharmaceuticals Inc (NASDAQ: ORIC) has announced initial data from an ongoing Phase 1b study evaluating ORIC-101 in combination with nab-paclitaxel, in advanced solid tumors. Data will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting. As of the database cutoff date of April 21, the recommended dose of 160 mg of ORIC-101 was well-tolerated. Treatment-related adverse events were primarily mild or moderate, with only three severe events reported, all of which res

  • ORIC Pharmaceuticals Reports Initial Clinical Data Being Presented at ASCO from Phase 1b Trial of ORIC-101 in Combination with Nab-Paclitaxel
    GlobeNewswire

    ORIC Pharmaceuticals Reports Initial Clinical Data Being Presented at ASCO from Phase 1b Trial of ORIC-101 in Combination with Nab-Paclitaxel

    Initial safety data showed combination regimen at the recommended Phase 2 dose was well tolerated; treatment-related adverse events primarily Grade 1 or 2, with no treatment-related discontinuations ORIC-101 plasma concentrations provided excellent target coverage; no evidence of drug-drug interaction with nab-paclitaxel Translational data showed pharmacodynamic modulation of GR biomarkers and high rates of GR expression in tumor types of interest Antitumor activity demonstrated across multiple

  • ORIC Pharmaceuticals to Present at Jefferies Virtual Healthcare Conference
    GlobeNewswire

    ORIC Pharmaceuticals to Present at Jefferies Virtual Healthcare Conference

    SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, May 26, 2021 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that Jacob Chacko, M.D., chief executive officer, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on Friday, June 4, 2021, at 1:30 p.m. ET. A live webcast of the fireside chat will be available through the investor section of the company’s website at www.oricpharma.com. A replay of the webcast will be available for 90 days following the event. About ORIC Pharmaceuticals, Inc. ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients’ lives by Overcoming Resistance In Cancer. ORIC’s lead product candidate, ORIC-101, is a potent and selective small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeutics across a variety of solid tumors. ORIC-101 is currently in two separate Phase 1b trials in combination with (1) Abraxane (nab-paclitaxel) in advanced or metastatic solid tumors and (2) Xtandi (enzalutamide) in metastatic prostate cancer. ORIC’s other product candidates include (1) ORIC-533, an orally bioavailable small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy- and immunotherapy-based treatment regimens, (2) ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and (3) ORIC-114, a brain penetrant inhibitor designed to selectively target EGFR and HER2 with high potency against exon 20 insertion mutations, being developed across multiple genetically defined cancers. Beyond these four product candidates, ORIC is also developing multiple precision medicines targeting other hallmark cancer resistance mechanisms. ORIC has offices in South San Francisco and San Diego, California. For more information, please go to www.oricpharma.com, and follow us on Twitter or LinkedIn. Investor Contact:Dominic Piscitelli, Chief Financial Officerdominic.piscitelli@oricpharma.cominfo@oricpharma.com